Humoral immunity is the major component in resistance to CPV infection, and therefore prophylactic vaccination is the most effective means of control. Carmichael et al. (1981) characterised the ideal vaccine as one that should be (a) safe, (b) engender an early and vigorous immune response that endures, and (c) provide an immune barrier that interrupts spread of virulent virus. Whilst the development of homologous CPV vaccines was awaited, FPV vaccines prepared for use in cats were used with dogs. Owing to cross-antigenicity between FPV and CPV, FPV vaccines stimulated the production of antibodies in dogs which neutralised CPV particles on challenge infection. Unfortunately, such protection was short-lived and did not provide the desired immune barrier. The different types of vaccines that have been used in CPV prophylaxis are listed in Table 1 (See Page 18).
KeywordsAttenuation Hydroxide Protec Rubella Lymphopenia
Unable to display preview. Download preview PDF.